Prostate cancer: How can we improve the health of men who receive ADT?

Nature Reviews Urology

Volumn 6, Issue 10, 2009, Pages 529-531

  Saylor, Philip J ^a   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; GONADORELIN AGONIST; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASTRATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG SAFETY; DRUG USE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MALE; MEN'S HEALTH; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUDDEN DEATH; THERAPY EFFECT; WEIGHT GAIN;

GONADOTROPIN-RELEASING HORMONE; HEALTH STATUS; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 70349961780     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.195     Document Type: Article

References (10)

1. Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006).
2. Alibhai, S. M. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 27, 3452-3458 (2009).
3. Saigal, C. S. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110, 1493-1500 (2007).
4. Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M. H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516-1524 (2007).
5. Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
6. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 31 (Suppl. 1), S12-S54 (2008).
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
8. Pearson, T. A. et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106, 388-391 (2002).
9. Smith, M. R., Lee, H., Fallon, M. A. & Nathan, D. M. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71, 318-322 (2008).
10. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334 (2009).